NASDAQ:MRVI

Maravai LifeSciences Competitors

$35.82
-1.33 (-3.58 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$35.01
$37.80
50-Day Range
$32.03
$39.03
52-Week Range
$23.62
$40.24
Volume1.55 million shs
Average Volume1.40 million shs
Market Capitalization$9.23 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Maravai LifeSciences (NASDAQ:MRVI) Vs. BGNE, RPRX, GMAB, CVAC, HZNP, and CTLT

Should you be buying MRVI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Maravai LifeSciences, including BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), CureVac (CVAC), Horizon Therapeutics Public (HZNP), and Catalent (CTLT).

BeiGene (NASDAQ:BGNE) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Institutional & Insider Ownership

60.7% of BeiGene shares are held by institutional investors. 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BeiGene and Maravai LifeSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million64.96$-948,630,000.00($15.80)-19.20
Maravai LifeSciencesN/AN/AN/AN/AN/A

Maravai LifeSciences has lower revenue, but higher earnings than BeiGene.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for BeiGene and Maravai LifeSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
Maravai LifeSciences001003.00

BeiGene presently has a consensus target price of $317.1250, indicating a potential upside of 4.55%. Maravai LifeSciences has a consensus target price of $38.1250, indicating a potential upside of 6.43%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than BeiGene.

Profitability

This table compares BeiGene and Maravai LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Maravai LifeSciencesN/AN/AN/A

Summary

Maravai LifeSciences beats BeiGene on 6 of the 9 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Maravai LifeSciences (NASDAQ:MRVI) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Royalty Pharma and Maravai LifeSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Maravai LifeSciences001003.00

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 25.03%. Maravai LifeSciences has a consensus target price of $38.1250, suggesting a potential upside of 6.43%. Given Royalty Pharma's higher probable upside, equities research analysts clearly believe Royalty Pharma is more favorable than Maravai LifeSciences.

Profitability

This table compares Royalty Pharma and Maravai LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Maravai LifeSciencesN/AN/AN/A

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Royalty Pharma and Maravai LifeSciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Maravai LifeSciencesN/AN/AN/AN/AN/A

Summary

Royalty Pharma beats Maravai LifeSciences on 3 of the 5 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and Genmab A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Genmab A/S24902.47

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. Genmab A/S has a consensus price target of $41.5714, suggesting a potential upside of 11.63%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Maravai LifeSciences.

Profitability

This table compares Maravai LifeSciences and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Genmab A/S50.99%34.40%30.67%

Institutional & Insider Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and Genmab A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Genmab A/S$804.57 million30.36$324.68 million$0.5173.02

Genmab A/S has higher revenue and earnings than Maravai LifeSciences.

Summary

Genmab A/S beats Maravai LifeSciences on 6 of the 8 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and CureVac, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
CureVac11302.40

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. CureVac has a consensus price target of $58.3333, suggesting a potential downside of 44.86%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than CureVac.

Profitability

This table compares Maravai LifeSciences and CureVac's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
CureVacN/AN/AN/A

Institutional & Insider Ownership

4.3% of CureVac shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and CureVac's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
CureVacN/AN/AN/AN/AN/A

Summary

Maravai LifeSciences beats CureVac on 3 of the 4 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and Horizon Therapeutics Public, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Horizon Therapeutics Public001103.00

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. Horizon Therapeutics Public has a consensus price target of $111.3636, suggesting a potential upside of 29.13%. Given Horizon Therapeutics Public's higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than Maravai LifeSciences.

Profitability

This table compares Maravai LifeSciences and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Horizon Therapeutics Public43.55%25.66%14.19%

Institutional & Insider Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and Horizon Therapeutics Public's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Horizon Therapeutics Public$1.30 billion14.91$573.02 million$1.9444.45

Horizon Therapeutics Public has higher revenue and earnings than Maravai LifeSciences.

Summary

Horizon Therapeutics Public beats Maravai LifeSciences on 8 of the 8 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Catalent (NYSE:CTLT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Maravai LifeSciences and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Catalent9.25%14.20%4.83%

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and Catalent, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Catalent01702.88

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. Catalent has a consensus price target of $125.1250, suggesting a potential upside of 19.39%. Given Catalent's higher probable upside, analysts plainly believe Catalent is more favorable than Maravai LifeSciences.

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and Catalent's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Catalent$3.09 billion5.77$173 million$1.8855.74

Catalent has higher revenue and earnings than Maravai LifeSciences.

Summary

Catalent beats Maravai LifeSciences on 7 of the 9 factors compared between the two stocks.


Maravai LifeSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BeiGene logo
BGNE
BeiGene
1.3$303.32-2.9%$27.81 billion$428.21 million-15.01Earnings Announcement
Analyst Report
Analyst Revision
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$41.49-1.3%$25.19 billionN/A0.00
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.24-0.4%$24.42 billion$804.57 million28.87Earnings Announcement
Analyst Revision
CureVac logo
CVAC
CureVac
0.7$105.79-5.1%$19.77 billionN/A0.00Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$86.24-2.0%$19.38 billion$1.30 billion23.56Earnings Announcement
Catalent logo
CTLT
Catalent
1.7$104.80-2.6%$17.85 billion$3.09 billion66.75Earnings Announcement
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.24-2.0%$15.24 billion$3.07 billion-56.56Earnings Announcement
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$128.63-2.1%$15.12 billion$219.75 million-16.43
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.39-1.8%$13.96 billion$1.70 billion17.48Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$149.45-5.8%$13.33 billion$12.98 million-49.32
Grifols logo
GRFS
Grifols
1.3$18.60-2.0%$12.79 billion$5.71 billion16.61Earnings Announcement
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.20-1.6%$12.01 billion$2.32 billion59.67
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.25-1.5%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.10-0.9%$10.02 billion$2.16 billion55.55Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
2.1$27.53-2.0%$9.87 billion$8.60 billion-5.05
United Therapeutics logo
UTHR
United Therapeutics
1.7$189.88-2.9%$8.51 billion$1.45 billion17.96Earnings Announcement
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$147.63-2.5%$7.58 billion$3.34 million-19.17Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$109.25-4.8%$7.37 billion$103.71 million-24.89Earnings Announcement
Analyst Report
Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$130.07-2.2%$6.99 billion$14.98 million-15.84Upcoming Earnings
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$46.47-3.4%$6.94 billion$40.56 million-13.63Earnings Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.10-0.4%$6.88 billion$87.99 million-78.69Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$43.12-0.4%$5.76 billion$4.84 billion-718.55
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.03-6.5%$5.59 billion$380.83 million-8.96Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.21-2.9%$5.38 billion$66.51 million17.01
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$37.90-6.1%$5.36 billion$150,000.00-17.88News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.24-0.8%$5.11 billion$1.12 billion75.50Earnings Announcement
Allakos logo
ALLK
Allakos
1.7$94.95-6.3%$5.08 billionN/A-34.65News Coverage
Galapagos logo
GLPG
Galapagos
1.3$73.54-2.0%$4.82 billion$1.00 billion-11.14Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.6$64.01-6.8%$4.48 billion$85.54 million0.00News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.89-0.2%$4.38 billion$6.87 million-7.24Earnings Announcement
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$69.34-3.0%$4.30 billionN/A-5.65Earnings Announcement
News Coverage
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$56.74-4.5%$4.08 billion$4.31 million-1.96
LEGN
Legend Biotech
1.3$29.34-2.6%$3.90 billion$64.39 million0.00
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.75-0.1%$3.90 billion$117.91 million-11.31
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$63.27-2.4%$3.84 billion$806.43 million-8.96Earnings Announcement
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$24.99-5.0%$3.72 billion$204.89 million-31.24
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.15-4.3%$3.63 billionN/A-6.08
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.73-1.9%$3.60 billion$114.62 million-7.96Earnings Announcement
Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$21.65-1.7%$3.47 billion$1.17 billion-47.05High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.02-0.2%$3.37 billion$339.08 million-12.22Earnings Announcement
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$111.76-2.8%$3.29 billionN/A-55.60Earnings Announcement
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$59.87-2.9%$3.21 billion$1.11 billion19.25
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$62.93-3.2%$3.09 billionN/A-17.93Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$84.76-0.4%$3.07 billion$26.52 million-7.47Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$61.39-3.6%$3.01 billion$42.98 million-23.98
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$35.97-2.6%$2.92 billion$60,000.00-11.17
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.60-2.5%$2.82 billion$644.77 million-10.50Upcoming Earnings
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.90-3.4%$2.74 billion$306.98 million-5.57Earnings Announcement
Insmed logo
INSM
Insmed
1.2$25.99-25.4%$2.68 billion$136.47 million-10.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.